amodiaquine has been researched along with Adverse Drug Event in 8 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "6 mg/kg of amodiaquine per day) for the treatment of children and adults with uncomplicated falciparum malaria." | 9.16 | The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Quang, HH; Shanks, GD; Thanh, NX; Trung, TN, 2012) |
| " No statistical significant differences were observed in the occurrence of adverse events among treatment groups." | 6.80 | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. ( Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015) |
| " Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee." | 5.46 | Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. ( Aba, YT; Assi, SB; Bissagnéné, E; Duparc, S; Lameyre, V; Nguessan, AF; San, KM; Tanoh, MA; Tchiekoi, NB; Yavo, JC, 2017) |
| "6 mg/kg of amodiaquine per day) for the treatment of children and adults with uncomplicated falciparum malaria." | 5.16 | The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. ( Chavchich, M; Dai, B; Edstein, MD; Phong, NC; Quang, HH; Shanks, GD; Thanh, NX; Trung, TN, 2012) |
| "Methylene blue (MB) has been shown to be safe and effective against falciparum malaria in Africa and to have pronounced gametocytocidal properties." | 2.80 | Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. ( Berens-Riha, N; Bountogo, M; Bousema, T; Breitkreutz, J; Coulibaly, B; Drakeley, C; Kieser, M; Klose, C; Meissner, PE; Mockenhaupt, FP; Müller, O; Nebié, E; Pritsch, M; Schirmer, RH; Sié, A; Sirima, SB; Wieser, A, 2015) |
| " No statistical significant differences were observed in the occurrence of adverse events among treatment groups." | 2.80 | Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. ( Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015) |
| "Methylene blue (MB) was the first synthetic antimalarial drug ever used, and recent studies have been promising with regard to its revival in malaria therapy." | 2.73 | Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. ( Coulibaly, B; Klose, C; Kouyaté, B; Mansmann, U; Meissner, P; Mockenhaupt, FP; Müller, O; Schirmer, RH; Sié, A; Walter-Sack, I; Zoungrana, A, 2008) |
| " Adverse events (AEs) were documented at the home visit or during any unexpected visit to the Health Centre or to the hospital and coded and adjudicated by a local pharmacovigilance committee." | 1.46 | Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire. ( Aba, YT; Assi, SB; Bissagnéné, E; Duparc, S; Lameyre, V; Nguessan, AF; San, KM; Tanoh, MA; Tchiekoi, NB; Yavo, JC, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coulibaly, B | 2 |
| Pritsch, M | 1 |
| Bountogo, M | 1 |
| Meissner, PE | 1 |
| Nebié, E | 1 |
| Klose, C | 2 |
| Kieser, M | 1 |
| Berens-Riha, N | 1 |
| Wieser, A | 1 |
| Sirima, SB | 1 |
| Breitkreutz, J | 1 |
| Schirmer, RH | 2 |
| Sié, A | 2 |
| Mockenhaupt, FP | 2 |
| Drakeley, C | 1 |
| Bousema, T | 1 |
| Müller, O | 2 |
| Ouldabdallahi, M | 1 |
| Alew, I | 1 |
| Salem, MS | 1 |
| Dit Dialaw Ba, M | 1 |
| Boukhary, AO | 1 |
| Khairy, ML | 1 |
| Aziz, MB | 1 |
| Ringwald, P | 1 |
| Basco, LK | 1 |
| Niang, SD | 1 |
| Lebatt, SM | 1 |
| Ogutu, B | 1 |
| Juma, E | 1 |
| Obonyo, C | 1 |
| Jullien, V | 1 |
| Carn, G | 1 |
| Vaillant, M | 1 |
| Taylor, WR | 1 |
| Kiechel, JR | 1 |
| Nji, AM | 1 |
| Ali, IM | 1 |
| Moyeh, MN | 1 |
| Ngongang, EO | 1 |
| Ekollo, AM | 1 |
| Chedjou, JP | 1 |
| Ndikum, VN | 1 |
| Evehe, MS | 1 |
| Froeschl, G | 1 |
| Heumann, C | 1 |
| Mansmann, U | 2 |
| Ogundahunsi, O | 1 |
| Mbacham, WF | 1 |
| Assi, SB | 1 |
| Aba, YT | 1 |
| Yavo, JC | 1 |
| Nguessan, AF | 1 |
| Tchiekoi, NB | 1 |
| San, KM | 1 |
| Bissagnéné, E | 1 |
| Duparc, S | 1 |
| Lameyre, V | 1 |
| Tanoh, MA | 1 |
| Yusof, W | 1 |
| Gan, SH | 1 |
| Thanh, NX | 1 |
| Trung, TN | 1 |
| Phong, NC | 1 |
| Quang, HH | 1 |
| Dai, B | 1 |
| Shanks, GD | 1 |
| Chavchich, M | 1 |
| Edstein, MD | 1 |
| Zoungrana, A | 1 |
| Walter-Sack, I | 1 |
| Kouyaté, B | 1 |
| Meissner, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children[NCT01407887] | Phase 2 | 180 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon[NCT01845701] | Phase 3 | 720 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [NCT00354380] | Phase 2 | 0 participants | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for amodiaquine and Adverse Drug Event
3 other studies available for amodiaquine and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinati | 2014 |
Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d'Ivoire.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amodiaquine; Antimalarials; Artemisinins; Child; Child, | 2017 |
High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population.
Topics: Alleles; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Aryl Hydrocarbon Hydroxylases; Asian | 2009 |